Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis

The prognostic value of serum neurofilament light chain (sNfL), a biomarker of neurodegeneration, compared to other prognostic factors of amyotrophic lateral sclerosis (ALS) at the time of diagnosis, remains unclear.

[1]  J. Kassubek,et al.  Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[2]  P. Andersen,et al.  Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion , 2018, Annals of neurology.

[3]  A. Chiò,et al.  Cardiovascular diseases may play a negative role in the prognosis of amyotrophic lateral sclerosis , 2018, European journal of neurology.

[4]  Karel G M Moons,et al.  Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model , 2018, The Lancet Neurology.

[5]  F. Salachas,et al.  Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis , 2018, Neurology.

[6]  O. Witte,et al.  Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease , 2017, Neurology.

[7]  O. Hardiman,et al.  Survival prediction in Amyotrophic lateral sclerosis based on MRI measures and clinical characteristics , 2017, BMC Neurology.

[8]  Henrik Zetterberg,et al.  Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa , 2016, Clinical chemistry and laboratory medicine.

[9]  P. Andersen,et al.  Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis , 2015, Annals of neurology.

[10]  P. Andersen,et al.  Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[11]  N. Pearce,et al.  Neurofilament light chain , 2015, Neurology.

[12]  M. Copetti,et al.  Cerebrospinal fluid neurofilament light chain levels: marker of progression to generalized amyotrophic lateral sclerosis , 2015, European journal of neurology.

[13]  Gavin Giovannoni,et al.  Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[14]  Matthew C. Kiernan,et al.  Clinical diagnosis and management of amyotrophic lateral sclerosis , 2011, Nature Reviews Neurology.

[15]  Bernhard Hemmer,et al.  Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies , 2011, Multiple sclerosis international.

[16]  David M. Rissin,et al.  Single-Molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations , 2010, Nature Biotechnology.

[17]  E. Beghi,et al.  Prognostic factors in ALS: A critical review , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[18]  D. Goodin,et al.  Dissociating apathy and depression in Parkinson disease , 2006, Neurology.

[19]  R. Forbes,et al.  Are the El Escorial and Revised El Escorial criteria for ALS reproducible? A study of inter-observer agreement , 2001, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[20]  O. Hardiman,et al.  Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: A population-based study. , 2000, Archives of neurology.

[21]  A. Chiò,et al.  Factors predicting survival in ALS: a multicenter Italian study , 2016, Journal of Neurology.

[22]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .